Robust cullin-RING ligase function is established by a multiplicity of poly-ubiquitylation pathways

  1. Spencer Hill
  2. Kurt Reichermeier
  3. Daniel C Scott
  4. Lorena Samentar
  5. Jasmin Coulombe-Huntington
  6. Luisa Izzi
  7. Xiaojing Tang
  8. Rebeca Ibarra
  9. Thierry Bertomeu
  10. Annie Moradian
  11. Michael J Sweredoski
  12. Nora Caberoy
  13. Brenda A Schulman
  14. Frank Sicheri
  15. Mike Tyers
  16. Gary Kleiger  Is a corresponding author
  1. University of Nevada, Las Vegas, United States
  2. Genentech Inc, United States
  3. St Jude Children's Research Hospital, United States
  4. University of Montreal, Canada
  5. Mount Sinai Hospital, Canada
  6. California Institute of Technology, United States

Abstract

The cullin-RING ligases (CRLs) form the major family of E3 ubiquitin ligases. The prototypic CRLs in yeast, called SCF enzymes, employ a single E2 enzyme, Cdc34, to build poly-ubiquitin chains required for degradation. In contrast, six different human E2 and E3 enzyme activities, including Cdc34 orthologs UBE2R1 and UBE2R2, appear to mediate SCF-catalyzed substrate polyubiquitylation in vitro. The combinatorial interplay of these enzymes raises questions about genetic buffering of SCFs in human cells and challenges the dogma that E3s alone determine substrate specificity. To enable the quantitative comparisons of SCF-dependent ubiquitylation reactions with physiological enzyme concentrations, mass spectrometry was employed to estimate E2 and E3 levels in cells. In combination with UBE2R1/2, the E2 UBE2D3 and the E3 ARIH1 both promoted SCF-mediated polyubiquitylation in a substrate-specific fashion. Unexpectedly, UBE2R2 alone had negligible ubiquitylation activity at physiological concentrations and the ablation of UBE2R1/2 had no effect on the stability of SCF substrates in cells. A genome-wide CRISPR screen revealed that an additional E2 enzyme, UBE2G1, buffers against the loss of UBE2R1/2. UBE2G1 had robust in vitro chain extension activity with SCF, and UBE2G1 knockdown in cells lacking UBE2R1/2 resulted in stabilization of the SCF substrates p27 and CYCLIN E as well as the CUL2-RING ligase substrate HIF1a. The results demonstrate the human SCF enzyme system is diversified by association with multiple catalytic enzyme partners.

Data availability

High through-put sequence data can be found at the GEO repository: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE136175

The following data sets were generated

Article and author information

Author details

  1. Spencer Hill

    Department of Chemistry and Biochemistry, University of Nevada, Las Vegas, Las Vegas, United States
    Competing interests
    No competing interests declared.
  2. Kurt Reichermeier

    Departments of Discovery Proteomics and Discovery Oncology, Genentech Inc, South San Francisco, United States
    Competing interests
    Kurt Reichermeier, is an employee of the Genetech Biotechnology Compnay.
  3. Daniel C Scott

    Department of Structural Biology, St Jude Children's Research Hospital, Memphis, United States
    Competing interests
    No competing interests declared.
  4. Lorena Samentar

    School of Life Sciences, University of Nevada, Las Vegas, Las Vegas, United States
    Competing interests
    No competing interests declared.
  5. Jasmin Coulombe-Huntington

    Institute for Research in Immunology and Cancer, Department of Medicine, University of Montreal, Montreal, Canada
    Competing interests
    No competing interests declared.
  6. Luisa Izzi

    Institute for Research in Immunology and Cancer, Department of Medicine, University of Montreal, Montreal, Canada
    Competing interests
    No competing interests declared.
  7. Xiaojing Tang

    Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Canada
    Competing interests
    No competing interests declared.
  8. Rebeca Ibarra

    Department of Chemistry and Biochemistry, University of Nevada, Las Vegas, Las Vegas, United States
    Competing interests
    No competing interests declared.
  9. Thierry Bertomeu

    Institute for Research in Immunology and Cancer, Department of Medicine, University of Montreal, Montreal, Canada
    Competing interests
    No competing interests declared.
  10. Annie Moradian

    Proteome Exploration Laboratory, Division of Biology and Biological Engineering, Beckman Institute, California Institute of Technology, Pasadena, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0407-2031
  11. Michael J Sweredoski

    Proteome Exploration Laboratory, Division of Biology and Biological Engineering, Beckman Institute, California Institute of Technology, Pasadena, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0878-3831
  12. Nora Caberoy

    School of Life Sciences, University of Nevada, Las Vegas, Las Vegas, United States
    Competing interests
    No competing interests declared.
  13. Brenda A Schulman

    Department of Structural Biology, St Jude Children's Research Hospital, Memphis, United States
    Competing interests
    No competing interests declared.
  14. Frank Sicheri

    Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Canada
    Competing interests
    Frank Sicheri, is a founder and consultant for Repare Therapeutics.
  15. Mike Tyers

    Institute for Research in Immunology and Cancer, Department of Medicine, University of Montreal, Montreal, Canada
    Competing interests
    No competing interests declared.
  16. Gary Kleiger

    Department of Chemistry and Biochemistry, University of Nevada, Las Vegas, Las Vegas, United States
    For correspondence
    gary.kleiger@unlv.edu
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3924-1680

Funding

National Institutes of Health (2 R15 GM117555-02)

  • Spencer Hill
  • Rebeca Ibarra
  • Gary Kleiger

National Institutes of Health (R37GM069530)

  • Daniel C Scott
  • Brenda A Schulman

National Institutes of Health (P30CA021765)

  • Daniel C Scott
  • Brenda A Schulman

St. Jude Children's Research Hospital (ALSAC)

  • Daniel C Scott
  • Brenda A Schulman

Max-Planck-Gesellschaft

  • Brenda A Schulman

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Ivan Dikic, Goethe University Frankfurt, Germany

Version history

  1. Received: August 17, 2019
  2. Accepted: December 22, 2019
  3. Accepted Manuscript published: December 23, 2019 (version 1)
  4. Version of Record published: January 22, 2020 (version 2)

Copyright

© 2019, Hill et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,770
    Page views
  • 520
    Downloads
  • 28
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Spencer Hill
  2. Kurt Reichermeier
  3. Daniel C Scott
  4. Lorena Samentar
  5. Jasmin Coulombe-Huntington
  6. Luisa Izzi
  7. Xiaojing Tang
  8. Rebeca Ibarra
  9. Thierry Bertomeu
  10. Annie Moradian
  11. Michael J Sweredoski
  12. Nora Caberoy
  13. Brenda A Schulman
  14. Frank Sicheri
  15. Mike Tyers
  16. Gary Kleiger
(2019)
Robust cullin-RING ligase function is established by a multiplicity of poly-ubiquitylation pathways
eLife 8:e51163.
https://doi.org/10.7554/eLife.51163

Share this article

https://doi.org/10.7554/eLife.51163

Further reading

    1. Biochemistry and Chemical Biology
    2. Medicine
    Giulia Leanza, Francesca Cannata ... Nicola Napoli
    Research Article

    Type 2 diabetes (T2D) is associated with higher fracture risk, despite normal or high bone mineral density. We reported that bone formation genes (SOST and RUNX2) and advanced glycation end-products (AGEs) were impaired in T2D. We investigated Wnt signaling regulation and its association with AGEs accumulation and bone strength in T2D from bone tissue of 15 T2D and 21 non-diabetic postmenopausal women undergoing hip arthroplasty. Bone histomorphometry revealed a trend of low mineralized volume in T2D (T2D 0.249% [0.156–0.366]) vs non-diabetic subjects 0.352% [0.269–0.454]; p=0.053, as well as reduced bone strength (T2D 21.60 MPa [13.46–30.10] vs non-diabetic subjects 76.24 MPa [26.81–132.9]; p=0.002). We also showed that gene expression of Wnt agonists LEF-1 (p=0.0136) and WNT10B (p=0.0302) were lower in T2D. Conversely, gene expression of WNT5A (p=0.0232), SOST (p<0.0001), and GSK3B (p=0.0456) were higher, while collagen (COL1A1) was lower in T2D (p=0.0482). AGEs content was associated with SOST and WNT5A (r=0.9231, p<0.0001; r=0.6751, p=0.0322), but inversely correlated with LEF-1 and COL1A1 (r=–0.7500, p=0.0255; r=–0.9762, p=0.0004). SOST was associated with glycemic control and disease duration (r=0.4846, p=0.0043; r=0.7107, p=0.00174), whereas WNT5A and GSK3B were only correlated with glycemic control (r=0.5589, p=0.0037; r=0.4901, p=0.0051). Finally, Young’s modulus was negatively correlated with SOST (r=−0.5675, p=0.0011), AXIN2 (r=−0.5523, p=0.0042), and SFRP5 (r=−0.4442, p=0.0437), while positively correlated with LEF-1 (r=0.4116, p=0.0295) and WNT10B (r=0.6697, p=0.0001). These findings suggest that Wnt signaling and AGEs could be the main determinants of bone fragility in T2D.

    1. Biochemistry and Chemical Biology
    Valentin Bohl, Nele Merret Hollmann ... Axel Mogk
    Research Article

    Heat stress can cause cell death by triggering the aggregation of essential proteins. In bacteria, aggregated proteins are rescued by the canonical Hsp70/AAA+ (ClpB) bi-chaperone disaggregase. Man-made, severe stress conditions applied during, e.g., food processing represent a novel threat for bacteria by exceeding the capacity of the Hsp70/ClpB system. Here, we report on the potent autonomous AAA+ disaggregase ClpL from Listeria monocytogenes that provides enhanced heat resistance to the food-borne pathogen enabling persistence in adverse environments. ClpL shows increased thermal stability and enhanced disaggregation power compared to Hsp70/ClpB, enabling it to withstand severe heat stress and to solubilize tight aggregates. ClpL binds to protein aggregates via aromatic residues present in its N-terminal domain (NTD) that adopts a partially folded and dynamic conformation. Target specificity is achieved by simultaneous interactions of multiple NTDs with the aggregate surface. ClpL shows remarkable structural plasticity by forming diverse higher assembly states through interacting ClpL rings. NTDs become largely sequestered upon ClpL ring interactions. Stabilizing ring assemblies by engineered disulfide bonds strongly reduces disaggregation activity, suggesting that they represent storage states.